Show simple item record

dc.contributor.authorPawlyn, C
dc.contributor.authorJackson, GH
dc.date.accessioned2019-03-18T11:48:51Z
dc.date.issued2019-02-02
dc.identifier.citationBritish journal of hospital medicine (London, England : 2005), 2019, 80 (2), pp. 91 - 98
dc.identifier.issn1750-8460
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3159
dc.identifier.doi10.12968/hmed.2019.80.2.91
dc.description.abstractMyeloma outcomes have improved dramatically over the last decade as a result of novel therapies, several of which are now commonly continued to disease relapse. Physicians who do not work in haematology are therefore more likely than ever before to be consulted by a patient with myeloma, either for an unrelated condition or with a side effect of myeloma or its treatment. Myeloma is also the cancer most likely to be diagnosed in accident and emergency departments or by the acute physician and so an awareness of its presentation and management is especially important in these settings to enable early diagnosis and limit the morbidity associated with end organ damage. This review summarizes the presenting features of disease, diagnostic criteria for myeloma and related plasma cell disorders, and discusses current management.
dc.formatPrint
dc.format.extent91 - 98
dc.languageeng
dc.language.isoeng
dc.publisherMA HEALTHCARE LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titlePhysicians, paraproteins and progress: diagnosis and management of myeloma.
dc.typeJournal Article
dcterms.dateAccepted2018-10-10
rioxxterms.versionofrecord10.12968/hmed.2019.80.2.91
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of hospital medicine (London, England : 2005)
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.publication-statusPublished
pubs.volume80
pubs.embargo.termsNot known
icr.researchteamMyeloma Biology and Therapeutics
dc.contributor.icrauthorPawlyn, Charlotte


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0